About NeoVista, Inc.

Board of Directors

David Guyer, MD

Biography

David Guyer, MD, joined SV Life Sciences in May 2006, prior to which he was the CEO, co-founder, and a director of Eyetech Pharmaceuticals, before that company's acquisition by OSI Pharmaceuticals in 2005. Eyetech was a biopharmaceutical company that specialized in the development and commercialization of novel therapeutics to treat diseases of the eye.

At Eyetech, David led the firm through a series of events representative of the life cycle of a venture-backed portfolio company. These included closing private financing rounds totaling approximately $170 million, and completing a $157 million initial public offering and a secondary financing. The company also gained FDA approval for Macugen, a drug to treat macular degeneration, and partnered with Pfizer to market Macugen in a deal valued at over $750 million. This product achieved net sales of $184 million in its launch year, in the top 8 percent of all recorded pharmaceutical launches. OSI Pharmaceuticals subsequently acquired Eyetech for $935 million.

Prior to founding Eyetech, David was Professor and Chairman of the Department of Ophthalmology at the NYU School of Medicine.

David received his BS from Yale College and his MD from Johns Hopkins Medical School.